Cargando…
Efficacy and safety of canakinumab, a long acting fully human anti-Interleukin-1β antibody, in systemic juvenile idiopathic arthritis with active systemic features: results from a phase III study
| Autores principales: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2011
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3194416/ http://dx.doi.org/10.1186/1546-0096-9-S1-O21 |
| _version_ | 1782213967387557888 |
|---|---|
| author | Ruperto, N Brunner, H Horneff, G Quartier, P Constantin, T Berkun, Y Erguven, M Kallinich, T Brik, R Wulffraat, NM Ferrandiz, MA Rutkowska-Sak, L Ozdogan, H McCann, L Lheritier, K Preiss, R Tseng, L Martini, A Lovell, DJ |
| author_facet | Ruperto, N Brunner, H Horneff, G Quartier, P Constantin, T Berkun, Y Erguven, M Kallinich, T Brik, R Wulffraat, NM Ferrandiz, MA Rutkowska-Sak, L Ozdogan, H McCann, L Lheritier, K Preiss, R Tseng, L Martini, A Lovell, DJ |
| author_sort | Ruperto, N |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-3194416 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2011 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-31944162011-10-18 Efficacy and safety of canakinumab, a long acting fully human anti-Interleukin-1β antibody, in systemic juvenile idiopathic arthritis with active systemic features: results from a phase III study Ruperto, N Brunner, H Horneff, G Quartier, P Constantin, T Berkun, Y Erguven, M Kallinich, T Brik, R Wulffraat, NM Ferrandiz, MA Rutkowska-Sak, L Ozdogan, H McCann, L Lheritier, K Preiss, R Tseng, L Martini, A Lovell, DJ Pediatr Rheumatol Online J Oral Presentation BioMed Central 2011-09-14 /pmc/articles/PMC3194416/ http://dx.doi.org/10.1186/1546-0096-9-S1-O21 Text en Copyright ©2011 Ruperto et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Oral Presentation Ruperto, N Brunner, H Horneff, G Quartier, P Constantin, T Berkun, Y Erguven, M Kallinich, T Brik, R Wulffraat, NM Ferrandiz, MA Rutkowska-Sak, L Ozdogan, H McCann, L Lheritier, K Preiss, R Tseng, L Martini, A Lovell, DJ Efficacy and safety of canakinumab, a long acting fully human anti-Interleukin-1β antibody, in systemic juvenile idiopathic arthritis with active systemic features: results from a phase III study |
| title | Efficacy and safety of canakinumab, a long acting fully human anti-Interleukin-1β antibody, in systemic juvenile idiopathic arthritis with active systemic features: results from a phase III study |
| title_full | Efficacy and safety of canakinumab, a long acting fully human anti-Interleukin-1β antibody, in systemic juvenile idiopathic arthritis with active systemic features: results from a phase III study |
| title_fullStr | Efficacy and safety of canakinumab, a long acting fully human anti-Interleukin-1β antibody, in systemic juvenile idiopathic arthritis with active systemic features: results from a phase III study |
| title_full_unstemmed | Efficacy and safety of canakinumab, a long acting fully human anti-Interleukin-1β antibody, in systemic juvenile idiopathic arthritis with active systemic features: results from a phase III study |
| title_short | Efficacy and safety of canakinumab, a long acting fully human anti-Interleukin-1β antibody, in systemic juvenile idiopathic arthritis with active systemic features: results from a phase III study |
| title_sort | efficacy and safety of canakinumab, a long acting fully human anti-interleukin-1β antibody, in systemic juvenile idiopathic arthritis with active systemic features: results from a phase iii study |
| topic | Oral Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3194416/ http://dx.doi.org/10.1186/1546-0096-9-S1-O21 |
| work_keys_str_mv | AT ruperton efficacyandsafetyofcanakinumabalongactingfullyhumanantiinterleukin1bantibodyinsystemicjuvenileidiopathicarthritiswithactivesystemicfeaturesresultsfromaphaseiiistudy AT brunnerh efficacyandsafetyofcanakinumabalongactingfullyhumanantiinterleukin1bantibodyinsystemicjuvenileidiopathicarthritiswithactivesystemicfeaturesresultsfromaphaseiiistudy AT horneffg efficacyandsafetyofcanakinumabalongactingfullyhumanantiinterleukin1bantibodyinsystemicjuvenileidiopathicarthritiswithactivesystemicfeaturesresultsfromaphaseiiistudy AT quartierp efficacyandsafetyofcanakinumabalongactingfullyhumanantiinterleukin1bantibodyinsystemicjuvenileidiopathicarthritiswithactivesystemicfeaturesresultsfromaphaseiiistudy AT constantint efficacyandsafetyofcanakinumabalongactingfullyhumanantiinterleukin1bantibodyinsystemicjuvenileidiopathicarthritiswithactivesystemicfeaturesresultsfromaphaseiiistudy AT berkuny efficacyandsafetyofcanakinumabalongactingfullyhumanantiinterleukin1bantibodyinsystemicjuvenileidiopathicarthritiswithactivesystemicfeaturesresultsfromaphaseiiistudy AT erguvenm efficacyandsafetyofcanakinumabalongactingfullyhumanantiinterleukin1bantibodyinsystemicjuvenileidiopathicarthritiswithactivesystemicfeaturesresultsfromaphaseiiistudy AT kallinicht efficacyandsafetyofcanakinumabalongactingfullyhumanantiinterleukin1bantibodyinsystemicjuvenileidiopathicarthritiswithactivesystemicfeaturesresultsfromaphaseiiistudy AT brikr efficacyandsafetyofcanakinumabalongactingfullyhumanantiinterleukin1bantibodyinsystemicjuvenileidiopathicarthritiswithactivesystemicfeaturesresultsfromaphaseiiistudy AT wulffraatnm efficacyandsafetyofcanakinumabalongactingfullyhumanantiinterleukin1bantibodyinsystemicjuvenileidiopathicarthritiswithactivesystemicfeaturesresultsfromaphaseiiistudy AT ferrandizma efficacyandsafetyofcanakinumabalongactingfullyhumanantiinterleukin1bantibodyinsystemicjuvenileidiopathicarthritiswithactivesystemicfeaturesresultsfromaphaseiiistudy AT rutkowskasakl efficacyandsafetyofcanakinumabalongactingfullyhumanantiinterleukin1bantibodyinsystemicjuvenileidiopathicarthritiswithactivesystemicfeaturesresultsfromaphaseiiistudy AT ozdoganh efficacyandsafetyofcanakinumabalongactingfullyhumanantiinterleukin1bantibodyinsystemicjuvenileidiopathicarthritiswithactivesystemicfeaturesresultsfromaphaseiiistudy AT mccannl efficacyandsafetyofcanakinumabalongactingfullyhumanantiinterleukin1bantibodyinsystemicjuvenileidiopathicarthritiswithactivesystemicfeaturesresultsfromaphaseiiistudy AT lheritierk efficacyandsafetyofcanakinumabalongactingfullyhumanantiinterleukin1bantibodyinsystemicjuvenileidiopathicarthritiswithactivesystemicfeaturesresultsfromaphaseiiistudy AT preissr efficacyandsafetyofcanakinumabalongactingfullyhumanantiinterleukin1bantibodyinsystemicjuvenileidiopathicarthritiswithactivesystemicfeaturesresultsfromaphaseiiistudy AT tsengl efficacyandsafetyofcanakinumabalongactingfullyhumanantiinterleukin1bantibodyinsystemicjuvenileidiopathicarthritiswithactivesystemicfeaturesresultsfromaphaseiiistudy AT martinia efficacyandsafetyofcanakinumabalongactingfullyhumanantiinterleukin1bantibodyinsystemicjuvenileidiopathicarthritiswithactivesystemicfeaturesresultsfromaphaseiiistudy AT lovelldj efficacyandsafetyofcanakinumabalongactingfullyhumanantiinterleukin1bantibodyinsystemicjuvenileidiopathicarthritiswithactivesystemicfeaturesresultsfromaphaseiiistudy |